Physician profile
Drue M Ferrante
NPI 1265427165
$9,523.29
in general payments reported to CMS, 2019-2025
41 companies · $1,662 in 2025
The $1,662 reported for 2025 was more than what 91% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $880 · 2020: $609 · 2021: $1,116 · 2022: $1,872 · 2023: $1,693 · 2024: $1,690 · 2025: $1,662.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,046.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,045.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,503.63 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Amgen INC. | $1,153.51 | 2019-2025 | Evenity, Repatha, Prolia |
| Lilly USA, LLC | $1,041.75 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $753.67 | 2019-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $675.65 | 2020-2025 | Farxiga, Breztri |
| Pfizer INC. | $633.11 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $390.67 | 2021-2024 | |
| Abbvie INC. | $330.32 | 2019-2024 | |
| Amarin Pharma, INC. | $247.33 | 2019-2022 | |
| Esperion Therapeutics, INC. | $204.05 | 2020-2023 | Nexletol |
| Abbott Laboratories | $194.71 | 2019-2025 | Freestyle Libre 3 |
| Astellas Pharma US INC | $192.88 | 2019-2025 | Veozah |
| Boston Scientific Corporation | $167.94 | 2024-2025 | Apollo Esg System, Watchman Flx |
| Biohaven Pharmaceuticals, INC. | $167.61 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $164.46 | 2022 |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Drue Ferrante listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.